ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Thirty-Two Years of Radiotherapy for T1 Anal Cancer: Patterns, Outcomes, and Side-effects at a Single Institution.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDefinitive chemoradiotherapy is the standard treatment for anal cancer, but the optimal management of small (T1) tumours remains unclear, as these tumours are underrepresented in prospective trials.
methodsWe retrospectively analysed all patients with T1 anal carcinoma treated with curative intent at the Medical University of Vienna between 1990 and 2022. Patient, tumour, and treatment characteristics were extracted. Outcomes included overall survival (OS), disease-free survival (DFS), colostomy-free survival (CFS), and acute and late toxicity. Kaplan-Meier estimates, log-rank tests, and univariable Cox regression were used for exploratory time-to-event analyses.
resultsFifty-five patients (median age 67 years, range 31-86; female/male ratio 2.4:1) were included. The median prescribed dose was 58 Gy; 45% received concurrent chemotherapy and 35% a brachytherapy boost. Five-year OS, DFS, and CFS were 84.7%, 80.1%, and 85.3%, respectively. Late grade 3 toxicity occurred in six patients (11%), exclusively after 2D/3D radiotherapy. No statistically significant OS or DFS differences were demonstrated for brachytherapy, chemotherapy, nodal involvement, or IMRT/VMAT in exploratory univariable analyses.
conclusionsPatients with T1 anal carcinoma achieved favourable long-term tumour control and organ preservation after definitive radiotherapy or chemoradiotherapy. Severe late toxicity was observed only after 2D/3D radiotherapy; however, concurrent changes in treatment technique, dose, target volumes, and treatment era preclude attribution of this observation to any single treatment component. Numerically favourable outcomes with brachytherapy and concurrent chemotherapy were observed, but these findings remain hypothesis-generating and require validation in prospective studies.
Indexed as
Identifiers
42782289What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.